Myrexis Development Pipeline
| Drug Candidate | Disease | Descriptional Status |
| MPC-3100 Hsp90 Inhibitor |
Cancer | Phase 1 completed |
| MPC-0767 Hsp90 Inhibitor Prodrug |
Cancer | Expect to submit IND in 1Q 2012 |
| MPC-8640 Cancer Metabolism Inhibitor Prodrug |
Cancer | IND-enabling studies ongoing. MPC-8640 is an orally bioavailable pro-drug of a follow-on to MPC-9528 |
| MPI-485520 Oral Anti-interferon |
Autoimmune Disease | Proof of concept established in an animal model of autoimmune disease. Lead optimization is ongoing |
Myrexis, Inc. is a biotechnology company focused on the development of small molecule therapeutics with novel chemical structures and distinct mechanisms of action. The Company has generated a strong pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis is focused on maximizing the therapeutic and commercial value of these molecules by developing potential first-in-class and/or best-in-class treatment options for patients with unmet needs.
